BioNTech (BNTX) Expected to Release Quarterly Earnings on Tuesday

BioNTech (NASDAQ:BNTX) is expected to announce its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to post earnings of $0.8470 per share and revenue of $1.17 billion for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The firm had revenue of $122.31 million during the quarter, compared to analysts’ expectations of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%. BioNTech’s revenue was down 59.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.60) earnings per share. On average, analysts expect BioNTech to post ($6.62) EPS for the current fiscal year and ($5.30) EPS for the next fiscal year.

BioNTech Stock Performance

BNTX stock opened at $86.86 on Tuesday. The stock’s 50 day simple moving average is $98.36 and its 200 day simple moving average is $97.44. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. BioNTech has a 12-month low of $79.52 and a 12-month high of $124.00. The stock has a market capitalization of $21.97 billion, a PE ratio of -11.09 and a beta of 1.25.

Insider Buying and Selling

In other BioNTech news, CEO Ugur Sahin sold 36,209 shares of the stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $95.37, for a total value of $3,453,252.33. Following the transaction, the chief executive officer owned 36,209 shares of the company’s stock, valued at approximately $3,453,252.33. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 807,209 shares of company stock worth $79,246,837 in the last three months. 19.20% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

BNTX has been the subject of a number of research analyst reports. Citigroup reduced their target price on BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a report on Wednesday, August 5th. Wall Street Zen downgraded BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. BMO Capital Markets cut BioNTech from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $128.00 to $105.00 in a research report on Tuesday, September 8th. UBS Group reiterated a “buy” rating on shares of BioNTech in a report on Wednesday, September 16th. Finally, Berenberg Bank set a $140.00 price objective on BioNTech in a report on Wednesday, September 16th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $125.80.

BioNTech Company Profile

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing medicines and vaccines based on messenger RNA and other immunotherapy technologies. The company’s research programs address cancer, infectious diseases, and other serious medical conditions.

BioNTech’s oncology portfolio includes individualized and off-the-shelf cancer immunotherapies, including mRNA-based treatments, cell therapies, antibody-based therapies, and immune-modulating approaches. Its infectious-disease activities include vaccine programs developed through proprietary platforms and collaborations.

In collaboration with Pfizer, BioNTech developed Comirnaty, an mRNA-based COVID-19 vaccine.